Product
Tusamitamab
Aliases
SAR408701, Tusamitamab ravtansine
Name
SAR408701
3 clinical trials
1 drug
4 indications
Indication
TumorIndication
Breast Cancer MetastaticIndication
Pancreatic Carcinoma MetastaticDrug
tusamitamabIndication
NSCLCClinical trial
Open-label Study Evaluating the Effect of Tusamitamab Ravtansine on the QTc Interval in Participants With Metastatic Solid TumorsStatus: Terminated, Estimated PCD: 2023-08-01
Clinical trial
Open-label, Phase 2 Study, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine in Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEAStatus: Active (not recruiting), Estimated PCD: 2024-03-06
Clinical trial
Open-label, Multi-cohort, Phase 2 Trial, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine (SAR408701) Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-08-30